News

The approval marks the first authorised treatment for cerebral folate deficiency, a rare genetic neurological disorder affecting brain folate transport. It followed a systematic review of published literature,

This marks the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage. JS001sc is independently developed by Junshi Biosciences as a subcutaneous

The collaboration will integrate NewcelX’s NCEL-101 with Eledon’s investigational anti-cluster of differentiation 40 ligand (anti-CD40L) monoclonal antibody, tegoprubart (AT-1501), to support durable, immune-protected islet replacement and develop a

Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist intended for chronic weight management in Chinese adults with obesity or who are overweight. It is

This marks the first FDA approval of a TYK2 inhibitor specifically for this indication. The regulator granted this approval following findings from the pivotal POETYK PsA-I and POETYK

This approval applies to patients who have undergone at least one prior treatment, including a proteasome inhibitor and an immunomodulatory agent. It aims to provide a new standard

The licences sourced from Carisma Therapeutics and the University of Pennsylvania include methods and constructs specifically engineered for function within these immune cell populations. The designs complement Liberate Bio’s

CordenPharma Colorado will occupy the entire premises under a 15-year lease. The new LEED Gold-certified facility has flexible laboratory configurations, advanced mechanical and utility systems, and waste management

AFTX-201 is being evaluated as a one-time intravenous gene therapy in adults with genetically confirmed BAG3 DCM. The therapy delivers a fully human, full-length BAG3 transgene using the